a year ago

Locate Bio Secures £9.2M for Spinal Fusion Bone Graft Development

  • Locate Bio, a UK-based orthobiologics company, raised £9.2M in funding led by Mercia Ventures and BGF

  • The company intends to use the funds to further enhance its clinical study of LDGraft, a bone graft substitute for spinal fusion

  • LDGraft received a US Food and Drug Administration (FDA) breakthrough device designation in 2023.

      • ProblemHealthcare

      "Improving spinal fusion outcomes by providing a reliable and effective bone graft substitute."

      Solution

      "Locate Bio's LDGraft, a bone graft substitute that combines a proprietary protein encapsulation method with an osteoconductive scaffold to deliver rhBMP-2 and promote bone growth."

      Covered on